{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:27:26Z","timestamp":1775705246977,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Tuberculosis (TB) represents a significant global public health challenge, with China identified as a high-burden country. Data on the prevalence of drug resistance is crucial for informing the selection of appropriate pharmacological interventions for the treatment of drug-resistant tuberculosis (DR-TB).To evaluate the prevalence and drug resistance patterns among patients with DR-TB in Heyuan City, China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All 291 patients registered between April 2021 and March 2023 were tested for drug resistance, and information about their medical history and demographics was collected directly from the hospital\u2019s computer database. Eight genes were analyzed for mutations associated with resistance to five antituberculosis drugs: the <jats:italic>katG<\/jats:italic>, <jats:italic>ahpC<\/jats:italic>, and <jats:italic>inhA<\/jats:italic> promoters for isoniazid (INH); <jats:italic>rpoB<\/jats:italic> for rifampicin (RIF); <jats:italic>embB<\/jats:italic> for ethambutol (EMB); <jats:italic>gyrA<\/jats:italic> for fluoroquinolones (FQs); and <jats:italic>rrs<\/jats:italic> and <jats:italic>rpsL<\/jats:italic> for streptomycin (STR). All strains were genotyped using fluorescence melting curve analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In Heyuan, 24.4% (71\/291) of patients with treatment-resistant TB were resistant to at least one drug. Following are the rates of general resistance to each drug: RIF (28\/272, 10.29%), INH (38\/274, 13.87%), FQs (10\/259, 3.86%), EMB (20\/248, 8.06%), and STR (15\/150, 10.00%). Age or gender had no statistically significant impact on the likelihood of developing drug resistance. Nevertheless, a statistically significant difference was observed between the three strategies of drug resistance testing, AFB testing, and MTB antibody testing. There were 48 cases of single-drug resistance and 23 cases of multiple-drug resistance among the 71 drug-resistant patients. Eight genes had 127 altered nucleotide sequences, with KatG315 (20.47%) having the most significant incidence of mutations. The top three mutated genes were <jats:italic>rpoB<\/jats:italic> (32.28%), <jats:italic>katG<\/jats:italic> (23.62%), and <jats:italic>embB<\/jats:italic> (15.75%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings may be helpful in Heyuan City for the quick molecular identification of DR-TB isolates in clinical samples.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1586938","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:29Z","timestamp":1749705689000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and molecular characterization of drug-resistant Mycobacterium tuberculosis in Heyuan City in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Dan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JianHong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhiFang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiangXing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.956171","article-title":"Evaluation of whole-genome sequence to predict drug resistance of nine anti-tuberculosis drugs and characterize resistance genes in clinical rifampicin-resistant Mycobacterium tuberculosis isolates from Ningbo, China","volume":"10","author":"Che","year":"2022","journal-title":"Front. In Public Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S1473-3099(21)00808-2","article-title":"25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward","volume":"22","author":"Dean","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.924410","article-title":"Improved conventional and new approaches in the diagnosis of tuberculosis","volume":"13","author":"Dong","year":"2022","journal-title":"Front. In Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/thx.2005.045963","article-title":"Risk factors for multidrug resistant tuberculosis in Europe: a systematic review","volume":"61","author":"Faustini","year":"2006","journal-title":"Thorax"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0022721","DOI":"10.1128\/cmr.00227-21","article-title":"Tuberculosis treatment monitoring and outcome measures: new interest and new strategies","volume":"35","author":"Heyckendorf","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2697230","DOI":"10.1155\/2020\/2697230","article-title":"Detection of eight respiratory bacterial pathogens based on multiplex real-time PCR with fluorescence melting curve analysis","volume":"2020","author":"Hu","year":"2020","journal-title":"Can. J. Infect. Dis. Med. Microbiol. = J. Canadien Des. Maladies Infectieuses Et la Microbiologie Medicale"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.943545","article-title":"Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management","volume":"12","author":"Liebenberg","year":"2022","journal-title":"Front. In Cell. Infection Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12866-021-02246-7","article-title":"Prevalence and molecular characteristics of drug-resistant mycobacterium tuberculosis in Hainan, China: from 2014 to 2019","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.1038\/s41598-019-43547-2","article-title":"Prevalence and molecular characterization of multidrug-resistant M","volume":"9","author":"Luo","year":"2019","journal-title":"tuberculosis Jiangxi province China. Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0221232","DOI":"10.1371\/journal.pone.0221232","article-title":"Epidemiology of tuberculous lymphadenitis in Denmark: A nationwide register-based study","volume":"14","author":"Mathiasen","year":"2019","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00537","DOI":"10.1128\/AAC.00537-20","article-title":"Genetic mutations associated with isoniazid resistance in mycobacterium tuberculosis in Mongolia","volume":"64","author":"Narmandakh","year":"2020","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/cid\/ciz932","article-title":"Multicenter study of the accuracy of the BD MAX multidrug-resistant tuberculosis assay for detection of mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid","author":"Shah","year":"2020","journal-title":"Clin. Infect. Diseases: an Off. Publ. Infect. Dis. Soc. America"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1021\/acs.accounts.0c00878","article-title":"Strategies to combat multi-drug resistance in tuberculosis","volume":"54","author":"Singh","year":"2021","journal-title":"Acc Chem. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijantimicag.2007.10.014","article-title":"Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates","volume":"31","author":"Sun","year":"2008","journal-title":"Int. J. Antimicrobial Agents"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","article-title":"Drug resistant TB - latest developments in epidemiology, diagnostics and management","author":"Tiberi","year":"2022","journal-title":"Int. J. Infect. Diseases: IJID: Off. Publ. Int. Soc. For Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jinf.2021.02.004","article-title":"Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey","volume":"82","author":"Wang","year":"2021","journal-title":"J. Infection"},{"key":"B18","volume-title":"Global tuberculosis report 2022","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1019198","article-title":"Transmission of multidrug-resistant tuberculosis in Beijing, China: An epidemiological and genomic analysis","volume":"10","author":"Yin","year":"2022","journal-title":"Front. Public Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1128\/AAC.01228-13","article-title":"Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1128\/AAC.02426-14","article-title":"Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1586938\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:29Z","timestamp":1749705689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1586938\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":21,"alternative-id":["10.3389\/fcimb.2025.1586938"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1586938","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1586938"}}